Get the Stockscreener App
3.51
3.54%
0.12
After Hours:
3.60
0.09
+2.56%
Genelux Corp stock is traded at $3.51, with a volume of 66,738.
It is up +3.54% in the last 24 hours and up +24.03% over the past month.
Genelux Corp is a clinical-stage biopharmaceutical company. The company focuses on developing next-generation oncolytic viral immunotherapies for patients suffering from aggressive or difficult-to-treat solid tumor types. Its pipeline products include Olvi-Vec (olvimulogene nanivacirepvec), Lung, and Pancreatic Cancer.
See More
Previous Close:
$3.39
Open:
$3.32
24h Volume:
66,738
Relative Volume:
0.46
Market Cap:
$132.54M
Revenue:
-
Net Income/Loss:
$-27.66M
P/E Ratio:
-3.6947
EPS:
-0.95
Net Cash Flow:
$-24.36M
1W Performance:
+5.09%
1M Performance:
+24.03%
6M Performance:
-11.14%
1Y Performance:
+79.08%
1-Day Range:
$3.32
$3.56
1-Week Range:
$3.30
$3.70
52-Week Range:
$1.60
$5.885
Genelux Corp Stock (GNLX) Company Profile
Name
Genelux Corp
Sector
Industry
Phone
805-267-9889
Address
2625 TOWNSGATE ROAD, SUITE 230, WESTLAKE VILLAGE
Compare GNLX with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
GNLX
Genelux Corp
|
3.51 | 128.01M | 0 | -27.66M | -24.36M | -0.95 |
|
VRTX
Vertex Pharmaceuticals Inc
|
462.13 | 117.32B | 11.10B | -988.90M | -1.26B | -3.92 |
|
REGN
Regeneron Pharmaceuticals Inc
|
558.87 | 58.89B | 14.09B | 4.50B | 2.96B | 39.28 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
401.80 | 51.14B | 2.46B | -319.09M | -52.09M | -2.47 |
|
ARGX
Argen X Se Adr
|
673.80 | 41.02B | 3.05B | 1.28B | -614.78M | 19.58 |
|
ONC
Beone Medicines Ltd Adr
|
299.01 | 32.59B | 3.81B | -644.79M | -669.77M | -6.24 |
Genelux Corp Stock (GNLX) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Oct-29-24 | Initiated | Guggenheim | Buy |
| Aug-28-24 | Initiated | ROTH MKM | Buy |
| Nov-27-23 | Initiated | H.C. Wainwright | Buy |
| Sep-12-23 | Initiated | Maxim Group | Buy |
| Feb-15-23 | Initiated | The Benchmark Company | Speculative Buy |
Genelux Corp Stock (GNLX) Latest News
Can trapped investors hope for a rebound in Genelux CorporationBuy Candidate Summary Based on Fundamentals - Newser
What are the latest earnings results for Genelux CorporationMarket Forecast Signals For Fast Growth - jammulinksnews.com
How Genelux Corporation stock performs during market volatilityCapital Growth Summary Over Five Years - Newser
How to use a screener to detect Genelux Corporation breakoutsDividend Strategy Summary With 10-Year Outlook - Newser
Genelux Corporation Added to High Probability Setup ListHigh Conviction Intraday Stock Signals Detected - metal.it
How Efficient Is Genelux Corporation at Controlling Operating CostsRisk Aware Swing Trade Analysis Insights - Newser
Does Genelux Corporation stock perform well during market downturnsAchieve unparalleled market performance - jammulinksnews.com
Using AI based signals to follow Genelux CorporationEarnings Report Summary with Market Impact - Newser
Is it the right time to buy Genelux Corporation stockGet alerts on the hottest market movers - jammulinksnews.com
What drives Genelux Corporation stock priceBreakthrough investment results - Autocar Professional
Genelux Corporation Stock Analysis and ForecastTriple returns potential - Autocar Professional
Genelux stock maintains Buy rating at H.C. Wainwright amid sector news - Investing.com India
Genelux stock maintains Buy rating at H.C. Wainwright amid sector news By Investing.com - Investing.com South Africa
Promising Prospects for Genelux Corp.’s Olvi-Vec: A Buy Rating Based on Strong Clinical Trial Design and Efficacy - TipRanks
What analysts say about Genelux Corporation stockOutstanding risk-reward balance - jammulinksnews.com
Lucid Capital Initiates Coverage on Genelux with a Buy Rating, Setting a Price Target of $10. - AInvest
Lucid Capital Initiates Coverage of Genelux with Buy Rating and $10 Price Target - AInvest
Genelux: LUCID CAPITAL MARKETS Initiates Buy Coverage, PT $10 - AInvest
Lucid Capital Markets initiates Genelux stock with Buy rating, $10 target By Investing.com - Investing.com South Africa
Lucid Capital Markets initiates Genelux stock with Buy rating, $10 target - Investing.com Nigeria
Genelux initiated with a Buy at Lucid Capital - TipRanks
Is Genelux Corporation a good long term investmentExceptional portfolio growth - Autocar Professional
Genelux Corp: A Promising Investment in the Oncolytic Virus Space with Key Clinical Milestones Ahead - TipRanks
What risks could impact Genelux Corporation stock performanceExpert Trading Flow - Newser
Genelux Corporation (NASDAQ:GNLX) Position Trimmed by Stratos Wealth Partners LTD. - Defense World
Why Genelux Corporation stock attracts strong analyst attentionProven Win Setups - Newser
What makes Genelux Corporation stock price move sharplyFree VIP Investment Strategies - Newser
Genelux (NASDAQ:GNLX) Raised to “Hold” at Wall Street Zen - Defense World
Amgen Alum Takes Legal Reins of Biotech Firm Developing Cancer Treatment - Law.com
Genelux Appoints Groen as General Counsel From Rani Therapeutics - Bloomberg Law News
Biopharma Co. Genelux Hires Life Sciences Veteran As GC - Law360
Genelux appoints Eric Groen as general counsel, corporate secretary, CCO - TipRanks
Genelux Corporation Announces Appointment of Eric Groen as General Counsel, Corporate Secretary, Chief Compliance Officer and Head of Business Development - MarketScreener
Former Amgen $10B Deal Architect Joins Genelux Leadership to Drive Strategic Growth - Stock Titan
Genelux Corporation (NASDAQ:GNLX) Receives Consensus Recommendation of “Buy” from Analysts - Defense World
June 2025's Promising Penny Stocks For Savvy Investors - simplywall.st
Two Sigma Investments LP Sells 18,446 Shares of Genelux Co. (NASDAQ:GNLX) - Defense World
Citadel Advisors LLC Lowers Position in Genelux Co. (NASDAQ:GNLX) - Defense World
Millennium Management LLC Cuts Stake in Genelux Co. (NASDAQ:GNLX) - Defense World
Genelux Co. (NASDAQ:GNLX) Shares Sold by Squarepoint Ops LLC - Defense World
Wall Street Zen Downgrades Genelux (NASDAQ:GNLX) to Sell - Defense World
Genelux Co. (NASDAQ:GNLX) Given Average Recommendation of “Buy” by Brokerages - Defense World
Genelux (NASDAQ:GNLX) Trading Up 3.3% – Time to Buy? - Defense World
Genelux Corp Stock (GNLX) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.93%
0.15%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):